Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lenalidomide - Celgene Corporation

Drug Profile

Lenalidomide - Celgene Corporation

Alternative Names: CC-5013; CDC-501; CDC-5013; ENMD-0997; IMiD-1; IMiD-3; Ladevina; Revimid™; REVLIMID

Latest Information Update: 28 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Developer Baylor College of Medicine; BeiGene; Celgene Corporation; Dana-Farber Cancer Institute; Groupe dEtude des Lymphomes de lAdulte; H. Lee Moffitt Cancer Center and Research Institute; Helsinki University Central Hospital; Indiana University School of Medicine; IRCCS San Raffaele; Massachusetts General Hospital; National Cancer Institute (USA); Nordic MDS Study Group; Novartis; Ohio State University Comprehensive Cancer Center; Peking Union Medical College Hospital; Roche; Roswell Park Cancer Institute; Royal Marsden NHS Foundation Trust; SCRI Development Innovations; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of California, Davis; University of Florida; University of Wuerzburg; Washington University School of Medicine; Weill Cornell Medical College
  • Class 2 ring heterocyclic compounds; Antineoplastics; Imides; Isoindoles; Piperidones; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Cell proliferation inhibitors; Immunomodulators; Interleukin 6 inhibitors; Tumour necrosis factor alpha inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Adult T-cell leukaemia-lymphoma; Myelodysplastic syndromes; Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes
  • Registered Adult T-cell leukaemia-lymphoma
  • Preregistration Non-Hodgkin's lymphoma
  • Phase III Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma
  • Phase II Acute myeloid leukaemia; Bladder cancer; Histiocytosis; Hodgkin's disease; Myelofibrosis; POEMS syndrome; Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
  • Phase I/II Non-small cell lung cancer
  • No development reported Cancer; Chronic myeloid leukaemia; Eye neoplasms; Glioblastoma; Peripheral T-cell lymphoma; Prostate cancer; Solid tumours
  • Discontinued Colorectal cancer; Heart failure; Inflammation; Liver cancer; Malignant melanoma

Most Recent Events

  • 28 Feb 2024 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Combination therapy, Second-line therapy or greater) in USA (PO, Capsule)
  • 31 Dec 2023 Beigene and Celgene Corporation terminates the license and supply agreement covering REVLIMID and VIDAZA as part of the settlement agreement
  • 09 Dec 2023 Efficacy and immunogenicity data from a phase III Myeloma XI trial in Multiple myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top